Status:
COMPLETED
Alpha-lipoic Acid in Diabetic Patients With Ischemic Cardiomyopathy
Lead Sponsor:
Damanhour University
Conditions:
Ischemic Cardiomyopathy
Diabetes Mellitus
Eligibility:
All Genders
20-75 years
Phase:
NA
Brief Summary
The aim of this study is to investigate the effect of alpha-lipoic acid on inflammatory markers and cardiac fibrosis markers in diabetic patients with Ischemic Cardiomyopathy.
Detailed Description
* A 3-month, prospective double blind interventional study, which will include 60 patients with type II Diabetes Mellitus with Ischemic Cardiomyopathy on optimal standard medical therapy, who will be ...
Eligibility Criteria
Inclusion
- Inclusion criteria:
- Type 2 diabetes with a history of CAD.
- LV ejection fraction (LVEF) ≤40%.
- Ischemic heart failure patients with NYHA grade II-IV.
- Exclusion criteria:
- Type 1 diabetes.
- Severe CKD with GFR ≤ 15 ml/min/1.73m\^2.
- Severe liver disease.
- Thyroid disorders.
- Acute febrile illness.
- Autoimmune disorders or connective tissue disorders.
Exclusion
Key Trial Info
Start Date :
March 1 2023
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
February 1 2024
Estimated Enrollment :
60 Patients enrolled
Trial Details
Trial ID
NCT06056687
Start Date
March 1 2023
End Date
February 1 2024
Last Update
February 21 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Damanhour Teaching Hospital, General Organization for Teaching Hospitals and Institutes.
Damanhūr, Elbehairah, Egypt, 31527